Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214083 · ClinicalTrials.gov registry record · Phase 2
N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT01214083: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT01214083 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01214083, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether: (1) the combination of N-acetylcysteine + high-dose naltrexone (150 mg) works better than high-dose naltrexone (150 mg) alone in reducing alcohol drinking; and (2) high-dose naltrexone (150 mg) alone works better than low-dose naltrexone (50 mg) alone in reducing alcohol drinking.
Interventions
- DRUG N-acetylcysteine + high-dose naltrexone (150 mg)
- DRUG High-dose naltrexone (150 mg) alone
- DRUG Low-dose naltrexone (50 mg) alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-10-15 |
| Est. Completion | 2016-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214083
The ClinicalTrials.gov registry entry for NCT01214083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which N-acetylcysteine + high-dose naltrexone (150 mg) is the first listed.
NCT01214083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214083 about?
NCT01214083 is a clinical study titled "N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence". The purpose of this study is to determine whether: (1) the combination of N-acetylcysteine + high-dose naltrexone (150 mg) works better than high-dose naltrexone (150 mg) alone in reducing alcohol drinking; and (2) high-dose naltrexone (150 mg) alone works better than low-dose naltrexone (50 mg) alo...
What is the current status of trial NCT01214083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2010-10-15. Estimated completion is 2016-10-30.
What interventions are being tested in trial NCT01214083?
The interventions under investigation include: N-acetylcysteine + high-dose naltrexone (150 mg) (DRUG), High-dose naltrexone (150 mg) alone (DRUG), Low-dose naltrexone (50 mg) alone (DRUG).
Who is sponsoring clinical trial NCT01214083?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.